# Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

Study · id `cardio:ct-nct07695701` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07695701](<https://clinicaltrials.gov/study/NCT07695701>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07695701

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT07695701. Allocation not applicable; no masking; primary purpose treatment. Start 2026-07 (anticipated); primary completion 2030-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT07695701, source copy `cardio:ctgov-nct07695701-2026-07-29`, retrieved 2026-10-31)
- Planned start: 2026-07 (anticipated) (ClinicalTrials.gov record NCT07695701, source copy `cardio:ctgov-nct07695701-2026-07-29`, retrieved 2026-10-31)
- Primary completion: 2030-08 (anticipated) (ClinicalTrials.gov record NCT07695701, source copy `cardio:ctgov-nct07695701-2026-07-29`, retrieved 2026-10-31)
- Completion: 2030-11 (anticipated) (ClinicalTrials.gov record NCT07695701, source copy `cardio:ctgov-nct07695701-2026-07-29`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT07695701, source copy `cardio:ctgov-nct07695701-2026-07-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07695701-2026-07-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
- Acronym: ASCEND-ATTR
- Condition: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
- Condition: Amyloidosis
- Condition: Amyloid Cardiomyopathy
- Condition: Transthyretin Amyloidosis
- Intervention (Drug): Acoramidis (AG10) oral tablet
- Lead sponsor: Eidos Therapeutics, a BridgeBio company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Eidos Therapeutics, a BridgeBio company (`cardio:org-eidos-therapeutics-a-bridgebio-company`)

## Provenance

Content hash: e43f4a5a9ecf422f3e124940319a42190e2025626fb17261eebe110baa04ac0c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
